Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.61 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | TERT | O14746 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | PPARD | Q03181 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15111134 | 1.00 | FAAH (0.61) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL1048698 | 1.00 | FAAH (0.61) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL5873301 | 1.00 | FAAH (0.61) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL545929 | 1.00 | FAAH (0.61) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL1150038 | 1.00 | FAAH (0.61) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL2280800 | 1.00 | FAAH (0.61) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL738863 | 1.00 | FAAH (0.61) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL6365469 | 1.00 | FAAH (0.61) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL6284899 | 1.00 | FAAH (0.61) | FAAHSOAT1CYP1A2CYP2C19KMT2A | |
| SCHEMBL1048697 | 1.00 | FAAH (0.61) | FAAHSOAT1CYP1A2CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108699307-B | Composition comprising a heterophasic propylene copolymer | SABIC环球技术有限责任公司 | 2021-07-09 | — | — | CN | disclosed |
| US-20100036115-A1 | Novel Compositions for the Delivery of Negatively Charged Molecules | SIRNA THERAPEUTICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7553830-B2 | Compositions for the delivery of negatively charged molecules | SIRNA THERAPEUTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1724254-A2 | Novel compositions for the delivery of negatively charged molecules | Sirna Therapeutics, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1019365-B1 | NOVEL COMPOSITIONS FOR THE DELIVERY OF NEGATIVELY CHARGED MOLECULES | SIRNA THERAPEUTICS INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050234232-A1 | Novel compositions for the delivery of negatively charged molecules | SIRNA THERAPEUTICS, INC. | 2005-10-20 | — | — | US | disclosed |
| US-6852315-B2 | Epoxidation of carbon-carbon double bond with membrane bound peroxygenase | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030073640-A1 | Novel compositions for the delivery of negatively charged molecules | RIBOZYME PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030040090-A1 | Epoxidation of carbon-carbon double bond with membrane bound peroxygenase | AGRICULTURE, UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY | 2003-02-27 | — | — | US | disclosed |
| US-6485949-B1 | Epoxidation of carbon-carbon double bond with membrane bound peroxygenase | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2002-11-26 | — | — | US | disclosed |
| US-6395713-B1 | CATIONIC LIPIDCATIONIC LIPID | RIBOZYME PHARMACEUTICALS, INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1019365-A4 | NOVEL COMPOSITIONS FOR THE DELIVERY OF NEGATIVELY CHARGED MOLECULES | RIBOZYME PHARM INC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-1019365-A1 | NOVEL COMPOSITIONS FOR THE DELIVERY OF NEGATIVELY CHARGED MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999005094-A1 | NOVEL COMPOSITIONS FOR THE DELIVERY OF NEGATIVELY CHARGED MOLECULES | RIBOZYME PHARMACEUTICALS, INCORPORATED (US) | 1999-02-04 | — | — | WO | disclosed |
| EP-0219548-B1 | POLYOLEFIN FOAM COMPOSITIONS HAVING IMPROVED DIMENSIONAL STABILITY UTILIZING CERTAIN UNSATURATED NITROGEN-CONTAINING COMPOUNDS ANDPROCESS FOR MAKING SAME | THE DOW CHEMICAL COMPANY (US) | 1990-06-13 | — | — | EP | disclosed |
| EP-0219548-A4 | POLYOLEFIN FOAM COMPOSITIONS HAVING IMPROVED DIMENSIONAL STABILITY UTILIZING CERTAIN UNSATURATED NITROGEN-CONTAINING COMPOUNDS ANDPROCESS FOR MAKING SAME. | DOW CHEMICAL CO (US) | 1988-03-23 | — | — | EP | disclosed |
| US-4694026-A | Polyolefin foam compositions having improved dimensional stability utilizing certain unsaturated nitrogen-containing compounds and process for making same | THE DOW CHEMICAL COMPANY (US) | 1987-09-15 | — | — | US | disclosed |
| EP-0219548-A1 | POLYOLEFIN FOAM COMPOSITIONS HAVING IMPROVED DIMENSIONAL STABILITY UTILIZING CERTAIN UNSATURATED NITROGEN-CONTAINING COMPOUNDS ANDPROCESS FOR MAKING SAME. | DOW CHEMICAL CO (US) | 1987-04-29 | — | — | EP | disclosed |
| WO-1986007076-A1 | POLYOLEFIN FOAM COMPOSITIONS HAVING IMPROVED DIMENSIONAL STABILITY UTILIZING CERTAIN UNSATURATED NITROGEN-CONTAINING COMPOUNDS ANDPROCESS FOR MAKING SAME | THE DOW CHEMICAL COMPANY (US) | 1986-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036115-A1 | Novel Compositions for the Delivery of Negatively Charged Molecules | PHAX, TARBP1, SNRPE | FAAH 4610/4885SOAT1 2626/4885CYP1A2 4883/4885 |
| US-20050234232-A1 | Novel compositions for the delivery of negatively charged molecules | PHAX, TARBP1, SNRPE | FAAH 4610/4885SOAT1 2626/4885CYP1A2 4883/4885 |
| US-20030073640-A1 | Novel compositions for the delivery of negatively charged molecules | PHAX, TARBP1, SNRPE | FAAH 4610/4885SOAT1 2626/4885CYP1A2 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.